ERBB2 and cancer: Moreover, metformin treatment efficiently reverses secondary resistance of HER2-overexpressing cancer cells to the dual HER1/HER2 tyrosine kinase inhibitor lapatinib (TykerbTM) by suppressing pro-survival pathways (i.e., the anti-apoptotic protein survivin) [109-111].